VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions

TIVERTON, R.I., June 18, 2007 /PRNewswire/ -- VeroScience, LLC, a privately held biotechnology and healthcare product development company, announced today that its late-breaking abstract has been accepted as a poster presentation at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Ill. The abstract, entitled, "Effects of Timed Cycloset(TM) (A Quick Release Formulation of Bromocriptine Mesylate) Administration of Safety, Cardiovascular Event Rate, and Glycemic Control in Subjects with Type 2 Diabetes Receiving Diet, Oral Hypoglycemic, and/or Insulin Treatment Regimens," will be included in the category of Clinical Therapeutics/New Technology - Pharmacologic Treatment of Diabetes or its Complications and displayed Saturday, Sunday and Monday, June 23-25, in the General Poster Session in the Exhibit Hall.

VeroScience is also sponsoring a corporate symposium supported by its commercialization partner for Cycloset(TM), S2 Therapeutics, Inc., that will be held in conjunction with the American Diabetes Association's 67th Scientific Sessions. The symposium, entitled "Evolution, Hypothalamic Dopamine Neurochemistry, and Developing New Therapies for Insulin Resistance Syndrome and Type 2 Diabetes," will be held on Sunday, June 24th from 5:30-7:45 AM at the Hyatt Regency Chicago, Grand F/D South. Registration and breakfast are from 5:00-5:30 AM or you can register in advance at www.veroscience.com/ada2007registration.

Cycloset(TM), an oral, quick-release formulation of bromocriptine is a centrally-acting dopamine D2 receptor agonist that is being studied as a potential therapy in the treatment of type 2 diabetes.

VeroScience is a privately held biotechnology and healthcare product development company with main offices and laboratories in Tiverton, RI. VeroScience has a large patent portfolio that supports its preclinical and clinical development programs and product pipeline in the areas of metabolism, immunology, reproduction, and oncology. VeroScience leverages its intellectual property and products in out-licensing and collaborative arrangements with appropriate industry partners.

S2 Therapeutics, a privately held specialty pharmaceutical company headquartered in Bristol, TN, is the commercialization partner for Cycloset(TM) and is the holder of an exclusive global license for the manufacture, marketing and distribution of Cycloset(TM). S2 seeks opportunities in the pharmaceutical industry through in-licensing arrangements and acquisitions of novel branded prescription pharmaceutical products.


    Contacts:

    Feinstein Kean Healthcare

    Christine Cramer, 617-761-6736

    
 
christine.cramer@fkhealth.com

CONTACT: Christine Cramer of Feinstein Kean Healthcare, +1-617-761-6736,, for VeroScience, LLC christine.cramer@fkhealth.com

Web site: http://www.veroscience.com/ada2007registration/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2007

View comments

Hide
(web1)